Merck's (MRK) pembrolizumab Receives Orphan Drug Status from FDA

AI Summary

Merck's (MRK) pembrolizumab has been granted orphan drug status by the FDA for treatment in neuroendocrine prostate cancer (NEPC). This designation is significant as it provides benefits such as market exclusivity and potential financial incentives for research and development. The orphan drug status can enhance Merck's positioning in the oncology market, potentially leading to increased sales once approved. The market impact could be positive as investors may view this as a step towards expanding Merck's product offerings in a niche area of cancer treatment.